WallStSmart

Cencora Inc. (COR)vsJohnson & Johnson (JNJ)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 240% more annual revenue ($337.40B vs $99.33B). JNJ leads profitability with a 16.2% profit margin vs 1.0%. COR appears more attractively valued with a PEG of 0.77. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 6.0Value: 5.3Quality: 3.8
Piotroski: 5/9

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-85.6%)

Margin of Safety

-85.6%

Fair Value

$193.43

Current Price

$359.03

$165.60 premium

UndervaluedFair: $193.43Overvalued

Intrinsic value data unavailable for JNJ.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 8.8/10
Return on EquityProfitability
94.6%10/10

Every $100 of equity generates 95 in profit

Market CapQuality
$66.67B9/10

Large-cap with strong market position

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Free Cash FlowQuality
$2.70B8/10

Generating 2.7B in free cash flow

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

Areas to Watch

COR4 concerns · Avg: 2.8/10
Price/BookValuation
18.6x4/10

Trading at 18.6x book value

Profit MarginProfitability
1.0%3/10

1.0% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Debt/EquityHealth
3.061/10

Elevated debt levels

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bear Case : COR

The primary concerns for COR are Price/Book, Profit Margin, Operating Margin. Debt-to-equity of 3.06 is elevated, increasing financial risk. Thin 1.0% margins leave little buffer for downturns.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.

Key Dynamics to Monitor

COR profiles as a value stock while JNJ is a mature play — different risk/reward profiles.

COR carries more volatility with a beta of 0.57 — expect wider price swings.

JNJ is growing revenue faster at 5.9% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

COR scores higher overall (62/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?